Selected highlights on women and HIV from the 5th Conference on Retroviruses and Opportunistic Infections.
Bartnof
H S
HS
D019380:Anti-HIV Agents / Q000097:blood / Q000493:pharmacokinetics; D002584:Cervix Uteri / Q000473:pathology / Q000821:virology; D002641:Chicago; D002986:Clinical Trials as Topic; D003226:Congresses as Topic; D016049:Didanosine / Q000097:blood / Q000493:pharmacokinetics; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000401:mortality; D017320:HIV Protease Inhibitors / Q000009:adverse effects / Q000097:blood; D006801:Humans; D019469:Indinavir / Q000009:adverse effects / Q000097:blood; D007674:Kidney Diseases / Q000139:chemically induced; D008297:Male; D008431:Maternal-Fetal Exchange; D008597:Menstrual Cycle / Q000502:physiology; D065006:Papanicolaou Test; D030361:Papillomavirus Infections / Q000453:epidemiology; D011247:Pregnancy; D012367:RNA, Viral / Q000097:blood*; D012307:Risk Factors; D014412:Tumor Virus Infections / Q000453:epidemiology; D014626:Vaginal Smears; D019562:Viral Load
D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D012367:RNA, Viral; D019469:Indinavir; D016049:Didanosine